The goal of the Hybridoma Facility is to produce monoclonal antibodies (MAbs) for use in characterizing, detecting, and purifying tumor antigens and other cancer-related proteins. The Facility generates MAbs primarily by fusing the spleens of antigen-immunized mice with a myeloma-derived fusion partner to immortalize antigen-specific antibodysecreting cells (hybridomas). The advantage of this approach is that it exploits the ability of the immune system of an intact animal to generate antibodies that react with antigens with high affinity, which can be used in a variety of applications that require the antibody to interact with target antigens with high specificity and sensitivity. Investigators often provide the facility with highly immunogenic glutathione-S-transferase (GST) fusion proteins, which in almost all cases generate a useful IgG-secreting MAb that recognizes the target antigen. In the most recent funding period, the Facility produced three classes of MAbs: 1)MAbs that recognize transcription factors and transcription factor domains for use in studies of cellular processes of oncogenesis;2) MAbs against molecules involved in RNA editing by microRNAs, which have emerged as crucial regulators of gene expression;and 3) antiidiotypic MAbs for use in cancer therapy. The facility has thus provided unique reagents to multiple Cancer Center members that have advanced their abilities to perform cutting edge research into underlying mechanisms of, and therapeutic approaches to cancer. In the most recent funding period the facility introduced hollow fiber bioreactors to enhance its capacity to produce large quantities of MAbs, and is beginning to perform custom-labeling of antibodies with fluorochromes and other tags to meet the increasing needs of investigators for labeled reagents for use in flow cytometry and other analysis systems. Another area being developed is the generation of human MAbs, using new methods combining flow cytometry, B cell activation via toll-like receptor ligands and immortalization with Epstein Barr virus. This technology provides the potential to develop reagents that can be used to treat human cancers and bypass problems with anti-mouse immune responses that develop in patients treated with mouse MAbs. This technology also offers the opportunity to analyze human B cell responses that may develop in disease states such as cancer.

Public Health Relevance

The Hybridoma Facility provides Cancer Center members with the ability to create and produce custom monoclonal antibodies to meet their needs to stain tissues, label cells, immunoprecipitate molecules or complexes, sort cells, and perform procedures that call for immunospecific reagents in cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Schug, Zachary T (2018) Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon ""Bi""-cycle. Biochemistry 57:889-890
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7
Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426

Showing the most recent 10 out of 741 publications